Welcome to my Digital Health Regulatory Pathways Master Class series.  This series breaks down the core concepts every founder should understand about US and EU regulatory pathways, from what qualifies as a medical device to how risk classification affects your timeline, cost, and market strategy.

You’ve landed on #3 of this series, where I explain the underlying differences between the FDR and the EU’s MDR and why they matter.

FDA vs. MDR – Two Very Different Worlds of Medical Device Regulation

If you’re a digital health founder preparing to launch a Software as a Medical Device (SaMD) or AI-enabled product, you’ve probably heard that the United States (FDA) and European Union (MDR) have different medical device regulations.

What many first-time founders don’t realize is just how different those systems are—and how much that difference can affect your time to market, costs, and documentation burden.  

This post breaks down the biggest structural contrasts between the FDA and MDR so you can make an informed decision about where to launch first—and what to prepare for.  While the two systems are aligning in some ways, these structural differences explain a lot about why the pathways in the US and EU are so different.

Centralized vs. Decentralized: The Big Structural Difference

FDA (United States)

In the U.S., medical device regulation is handled by one centralized federal agency: the Food and Drug Administration (FDA). Many low- and moderate-risk devices use the 510(k) premarket notification pathway, where you demonstrate that your product is “substantially equivalent” to an existing device. If the FDA agrees, your device is cleared—not “approved”—for market. This notification pathway was designed to support incremental innovation without regulatory barriers.

Importantly, the FDA’s approach allows you to bring low- to moderate-risk products to market more quickly and far more cheaply than the EU MDR pathway. Post-market, you’re required to notify the FDA of any serious issues, but you don’t need formal approval from the FDA unless you’re dealing with high-risk, Class III devices. Overall, the U.S. framework emphasizes speed and flexibility, particularly for startups working on novel but lower-risk technologies.

MDR (European Union)

In the EU, oversight of medical devices is decentralized. Devices are reviewed by Notified Bodies—private organizations designated by each Member State’s Competent Authorities—rather than a single centralized agency. Premarket access is granted through Notified Body review and certification, based on a detailed assessment of your technical documentation, risk management procedures, and quality management systems. The focus isn’t just on the product but on your entire manufacturing process and post-market surveillance strategy.

Importantly, the Medical Device Regulation (MDR) replaced the earlier Medical Device Directive (MDD) in 2017, with full implementation required by May 2021. Unlike directives, which EU countries implement individually through their own national laws, a regulation is directly applicable and enforceable across all Member States. This shift was intentional: the directive-based system led to inconsistent application, regulatory loopholes, and uneven enforcement across the EU. By adopting a regulation, the EU aimed to harmonize medical device oversight and ensure that safety standards were applied equally—regardless of where a device was reviewed or sold.

That harmonization effort translates to extensive documentation requirements under the MDR. Notified Bodies are tasked with verifying not only whether a product meets safety and performance standards, but also whether the manufacturer has robust systems in place to ensure ongoing compliance. This includes a comprehensive technical file, clinical evaluation reports, a Quality Management System, General Safety and Performance Requirements (GSPR) checklist, post-market surveillance plans, and detailed labeling and Instructions for Use. Risk management and benefit-risk analyses must be systematically documented, and updates must be maintained throughout the product lifecycle. The goal is to create a transparent paper trail that allows Notified Bodies to apply consistent criteria and gives regulators confidence in the device’s quality—regardless of which country it’s reviewed in. For startups, this means having to anticipate high costs in preparing this documentation. 

What This Means in Practice

The FDA maintains comparatively lean pathways for market entry—especially for Class I and II devices with a predicate. If you fit into that model, your regulatory path can be low-cost and relatively fast.

The EU MDR, on the other hand, requires extensive documentation even for lower-risk products, and emphasizes manufacturer compliance (not just product safety). The system is built to prioritize consistency and traceability across borders—not speed.

The Restaurant Inspection Analogy

Here’s a way to visualize it.

Imagine you run a restaurant.

  • The FDA is like a food inspector who tastes the dish, checks it against known recipes, and determines whether it’s similar to others already served safely. If it looks and tastes like food, it’s good to go.

     

  • A Notified Body, by contrast, is like a full-scale operations auditor. They’ll check your kitchen layout, food sourcing records, staff hygiene training, and hazard logs. The focus is on how you made the food—not just whether it’s edible.

     

That’s why MDR requires so much more upfront documentation—even for moderate-risk software.

Why The Difference Between FDA and MDR Pathways Matters to Startups

Founders often ask: Should we launch in the U.S. or Europe first?

From a regulatory perspective, here’s what matters:

  • The FDA pathways for low- and  moderate-risk devices are often faster, cheaper, and more predictable—especially if your product has a “predicate” (more on this later) and falls into Class I or II.

     

  • MDR pathways, especially since 2021, have grown more complex and expensive. Notified Body reviews are resource-intensive, and AI/SaMD products are often “up-classified” under MDR guidance—requiring NB review even for tools that might skate through approval or notification easily in the U.S.

     

  • Ironically, despite MDR’s goal of harmonization, interpretation still varies by Competent Authority, introducing uncertainty across different EU member states.

Up Next: Determining Risk Class—The First Step in Your Regulatory Strategy

In the next post, we’ll walk through how to classify your device’s risk level under both FDA and MDR systems.

Your risk class determines:

  • Which regulatory pathway you’ll follow
  • How much documentation and testing you’ll need
  • Whether clinical trials are expected
  • How long and expensive the process will be

Ask me anything.

Really.  If you have a question, submit it through this form. I will try my best to respond within a business day. Good questions will get featured on my FAQs list. 

Still have questions after exploring? Set up a quick meeting with me here.